GILLIS EDWARD M
Known title: Senior Vice President, DevicesCIK: 0001241359
Associated companies
Transaction History
| BCDA | ▼ Sell | Tax Withholding | 17,269 | $21K | 7/2/2026 | View on chart |
| BCDA | ▲ Buy | Grant | 39,521 | $47K | 6/29/2026 | View on chart |
| BCDA | ▼ Sell | Tax Withholding | 15,172 | $21K | 12/8/2025 | View on chart |
| BCDA | ▲ Buy | Grant | 38,078 | $52K | 12/8/2025 | View on chart |
| BCDA | ▼ Sell | Open Market | 3,257 | $7K | 12/20/2024 | View on chart |
| BCDA | ▲ Buy | Grant | 15,808 | $42K | 10/11/2024 | View on chart |
| BCDA | ▼ Sell | Tax Withholding | 6,840 | $18K | 10/11/2024 | View on chart |
| BCDA | ▼ Sell | Tax Withholding | 15,512 | $27K | 5/31/2023 | View on chart |
| BCDA | ▲ Buy | Grant | 40,490 | $69K | 5/18/2023 | View on chart |
| BCDA | ▼ Sell | Tax Withholding | 12,358 | $16K | 5/12/2022 | View on chart |
| BCDA | ▲ Buy | Grant | 30,155 | $0 | 4/14/2022 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 2, 2026
BioCardia Resubmits Helix Catheter Pre-Submission to FDA
BioCardia has filed a revised de‑novo pre‑submission and resubmitted a pre‑submission to the FDA for its Helix catheter, a device intended for therapeutic and diagnostic agent delivery to the heart. The filings are part of the regulatory pathway needed before the product can reach the market. The move is a significant step in the company’s development program and could influence investor perception of the company’s progress.
BioCardia Resubmits Helix Catheter Pre-Submission to FDA. BioCardia has filed a revised de‑novo pre‑submission and resubmitted a pre‑submission to the FDA for its Helix catheter, a device intended for therapeutic and diagnostic agent delivery to the heart. The filings are part of the regulatory pathway needed before the product can reach the market. The move is a significant step in the company’s development program and could influence investor perception of the company’s progress.